A practical reference on incretin: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-05-24 and is reviewed periodically as new material appears.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | Parent peptide; salt forms also reported |
| Molecular mass | about 4113.6 Da | Average mass of the free peptide |
| Peptide length | 31 amino acids | Backbone related to GLP-1(7-37) |
| Key substitution | Aib at position 8 | Blocks DPP-4 cleavage |
| Albumin binding | Via C-18 diacid side chain | Prolongs circulation time |
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Reported molecular weight is approximately 4113.6 daltons for the free base, and the peptide is supplied as a lyophilized powder or in buffered liquid form depending on the intended use. It is freely soluble in water when formulated with appropriate excipients, though the unconjugated peptide shows limited stability at neutral pH over long periods. Analytical characterization typically relies on reversed-phase high-performance liquid chromatography and mass spectrometry. Purity specifications for research-grade material commonly exceed ninety-five percent by area. Isotopic and impurity profiles differ between suppliers.
Two principal therapeutic variants exist under separate regulatory filings, one indicated for glycemic control in type 2 diabetes and one for chronic weight management. Both use the same active molecule; differences lie in formulation strength, titration schedule, and labeling. Regulatory agencies in the United States and European Union approved injectable forms in 2017 and 2018 respectively. An oral tablet formulation received approval later, using a carrier molecule to enhance absorption across the gastric epithelium. Labeling differs by jurisdiction and by indication.
The distinction between established facts and open questions matters here. That the peptide binds the GLP-1 receptor and stimulates insulin release in a glucose-dependent manner is well documented. How individual variability in receptor density, gastric emptying rate, and gut microbiome composition shapes response remains an active research area. Long-term outcomes beyond five years of continuous use are not yet fully characterized in published trials, and several extension studies are ongoing.
Actinium is found only in traces in uranium ores – one tonne of uranium in ore contains about 0.2 milligrams of 227Ac – and in thorium ores, which contain about 5 nanograms of 228Ac per one tonne of thorium. The actinium isotope 227Ac is a transient member of the uranium-actinium series decay chain, which begins with the parent isotope 235U (or 239Pu) and ends with the stable lead isotope 207Pb. The isotope 228Ac is a transient member of the thorium series decay chain, which begins with the parent isotope 232Th and ends with the stable lead isotope 208Pb. Another actinium isotope (225Ac) is transiently present in the neptunium series decay chain, beginning with 237Np (or 233U) and ending with thallium (205Tl) and near-stable bismuth (209Bi); even though all primordial 237Np has decayed away, it is continuously produced by neutron knock-out reactions on natural 238U. The low natural concentration and the close similarity of physical and chemical properties to those of lanthanum and other lanthanides, which are always abundant in actinium-bearing ores, render separation of actinium from the ore impractical. The most concentrated actinium sample prepared from raw material consisted of 7 micrograms of 227Ac in less than 0.1 milligrams of La2O3, and complete separation was never achieved. Instead, actinium is prepared, in milligram amounts, by the neutron irradiation of 226Ra in a nuclear reactor.
14 December Scientists report that genes inherited by modern humans from Neanderthals and Denisovans may biologically influence the daily routine of modern humans, specifically their chronotype. Astronomers report the first time discovery, in the plumes of Enceladus, moon of the planet Saturn, of hydrogen cyanide, a possible chemical essential for life as we know it, as well as other organic molecules, some of which are yet to be better identified and understood. According to the researchers, "these [newly discovered] compounds could potentially support extant microbial communities or drive complex organic synthesis leading to the origin of life." 15 December – Google DeepMind claims to have made the first ever scientific discovery with an AI chatbot by building a fact-checker to filter out useless outputs, leaving useful solutions to mathematical or computing problems. 19 December – COVID-19: The World Health Organization designates JN.1, part of the BA.2.86 SARS-CoV-2 lineage, as its own variant of interest. This follows a recent, rapid rise in case numbers around the world. 20 December A new class of antibiotic candidates, able to kill methicillin-resistant Staphylococcus aureus (MRSA) is identified using deep learning. An experimental study reports online search to evaluate the truthfulness of false news articles increases the probability of believing them, especially for those for whom search engines return lower-quality information. It suggests media literacy programs with tested strategies and solutions for identified search engines issues are needed.
Of all the African countries that were included in the survey, Ghana ranked highest. Tourism is the fourth highest earner of foreign exchange for the country. In 2024, Ghana ranked as the 55th most peaceful country in the world. Up and down the coastline, surfing spots have been identified and cultivated by locals and internationals. Surfers have made trips to the country to sample the waves. Surfers carried their boards amid traditional fishing vessels. According to Destination Pride, Ghana's Pride score is 22 (out of 100).
As of 2017, Oxandrolone was one of the few AASs that remained available for medical use in the United States. In June 2023, the FDA formally withdrew approval for oxandrolone for all indications, stating that possible adverse effects of the drug were sufficiently serious to warrant removal from the US market. The FDA decision was for reasons of safety or effectiveness, following a 2019 letter from Gemini, a drug manufacturer, stating that the product was no longer being marketed. As of August 2023, the AASs that remained available for medical use in the US were testosterone, testosterone cypionate, testosterone enanthate, testosterone undecanoate, methyltestosterone, fluoxymesterone, and oxymetholone.
Sources: en.wikipedia.org
=== Non-specific hydrophobic association === Amphitropic proteins associate with lipid bilayers via various hydrophobic anchor structures. Such as amphiphilic α-helixes, exposed nonpolar loops, post-translationally acylated or lipidated amino acid residues, or acyl chains of specifically bound regulatory lipids such as phosphatidylinositol phosphates. Hydrophobic interactions have been shown to be important even for highly cationic peptides and proteins, such as the polybasic domain of the MARCKS protein or histactophilin, when their natural hydrophobic anchors are present.
==== Pregnancy and breastfeeding ==== During pregnancy and breastfeeding, women must ingest enough nutrients for themselves and their child, so they need significantly more protein and calories during these periods, as well as more vitamins and minerals (especially iron, iodine, calcium, folic acid, and vitamins A, C, and K). In 2001 the FAO of the UN reported that iron deficiency affected 43 percent of women in developing countries and increased the risk of death during childbirth. A 2008 review of interventions estimated that universal supplementation with calcium, iron, and folic acid during pregnancy could prevent 105,000 maternal deaths (23.6 percent of all maternal deaths). Malnutrition has been found to affect three-quarters of UK women aged 16–49 indicated by them having less folic acid than the WHO recommended levels. Frequent pregnancies with short intervals between them and long periods of breastfeeding add an additional nutritional burden.
== Disorders of thyroid gland (240–246) == 240 Simple and unspecified goiter 240.9 Goiter, unspec. 241 Nontoxic nodular goiter 241.0 Thyroid nodule 241.9 Goiter, unspec. nontoxic nodular 242 Thyrotoxicosis with or without goiter 242.0 Goiter toxic, diffuse 242.9 Hyperthyroidism, NOS 243 Congenital hypothyroidism 244 Acquired hypothyroidism 244.0 Hypothyroidism, post-surgical 244.1 Hypothyroidism, post-ablative 244.9 Hypothyroidism, unspec. 245 Thyroiditis 245.0 Thyroiditis, acute 245.1 Thyroiditis, subacute 245.2 Thyroiditis, chronic, Hashimoto's 246 Other disorders of thyroid 246.2 Thyroid cyst
Sources: en.wikipedia.org
In March 2024, 10 children died at Kamal Adwan Hospital from dehydration and malnutrition, leading UNICEF to state, "Now, the child deaths we feared are here and are likely to rapidly increase unless the war ends and obstacles to humanitarian relief are immediately resolved". Doctors at Kamal Adwan stated all staff could give malnourished and dehydrated newborns was saline or sugar solution, with one pediatrician stating, "My message is an appeal to the entire world to intervene and save all the children". A severely malnourished 10-year-old boy named Yazan al-Kafarneh died from starvation. On 6 March 2024, WHO secretary-general Tedros Adhanom Ghebreyesus warned of "children who survived bombardment but may not survive a famine". The Palestinian Red Crescent found parents were going without food in order to feed "their hungry children amidst food insecurity and shortage of available food". Doctors at the Kamal Adwan Hospital stated malnourished infants in the ICU had become the "new normal". One doctor at Kamal Adwan stated, "Babies reach critical and severe degrees of dehydration and acidemia disorders and ultimately death." In June 2024, the director of the Kamal Adwan Hospital stated more than 200 children were at risk due to malnutrition. A clinical nutritionist stated that due to contaminated water and a lack of food security, 90 percent of children were experiencing diarrhea, hepatitis, and other diseases. Mothers were so malnourished they were unable to produce breastmilk to feed their newborn babies. Children continued to die from malnutrition in August 2024.
=== Other characters === Lonnie Anderson (Josh C. Williams, Luke Edwards, Kristopher Kent Hill) – Crystal's eldest child, born to her deceased husband, Sonny. Art (Dan Butler) – A divorced accountant to whom Roseanne and Jackie sell a motorcycle, and who provides tax services to Lanford Custom Cycle. Bob (John McConnell) – A close friend of Dan's. Dwight (William Sadler) – A buddy of Dan's who appears in the early seasons of Roseanne, who had a crush on Jackie. In The Conners, there is another character named Dwight who Dan appears to be friends with, but the character is not portrayed by William Sadler and might be a different character altogether. Fisher (Matt Roth) – Jackie's former long-time boyfriend, whom Dan ultimately went to jail for assaulting after learning he abused Jackie. Stacey Flagler (Traci Lords) – A waitress at the Lunchbox. George (Joseph Gordon-Levitt) – D.J.'s classmate. Gary Hall (Brian Kerwin) – Jackie's former fiancé. Heather (Heather Matarazzo) – D.J.'s girlfriend. Jimmy Meltrigger (Stephen Dorff) – Becky's former boyfriend from high school. Chip Lang (Jared Rushton) – Becky's former boyfriend from high school. Marla (Morgan Fairchild) – Nancy's girlfriend. Anne-Marie Mitchell (Adilah Barnes) – Roseanne's childhood friend, who is married to one of Dan's poker buddies, Chuckie. She and Chuck have a son, Chuck Jr., who is the same age as Lonnie and Darlene. Chuckie Mitchell (James Pickens Jr.) – Anne-Marie's husband, who occasionally worked with Dan.
=== GLUT 1 === Every carrier protein, especially within the same cell membrane, is specific to one type or family of molecules. GLUT1 is a named carrier protein found in almost all animal cell membranes that transports glucose across the bilayer. This protein is a uniporter, meaning it transports glucose along its concentration in a singular direction. It is an integral membrane protein carrier with a hydrophilic interior, which allows it to bind to glucose. As GLUT 1 is a type of carrier protein, it will undergo a conformational change to allow glucose to enter the other side of the plasma membrane. GLUT 1 is commonly found in the red blood cell membranes of mammals.
The cytochrome b5 reductase enzyme contains a typical oxidoreductase structure with a diaphorase binding domain complex for NADH and a FAD-binding domain. A three-stranded linker domain is present, as well as water-mediated hydrogen bonds, in order to biochemically connect the complex. Once cytochrome b5 reductase catalyzes electron transfer, the resulting reduced form of cytochrome b5 reduces the oxidized ferric ion of hemoglobin from Fe 3+ to Fe 2+. Mechanism: NADH + H+ + 2 ferricytochrome b5 -> NAD+ + 2 ferrocytochrome b5
Sources: en.wikipedia.org
It belongs to the incretin mimetic class and acts as a long-acting glucagon-like peptide-1 receptor agonist. The class includes several peptides with different half-lives and routes of administration.
The side chain enables reversible binding to albumin in the bloodstream, which protects the peptide from rapid renal clearance. This extends the interval between administrations compared with unmodified GLP-1.
No. It shares much of the native sequence but carries substitutions and an added side chain. These changes increase stability against enzymatic breakdown.
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and cleared quickly. Semaglutide carries a position 8 substitution that blocks that cleavage and a fatty diacid chain that binds albumin. Together these changes extend its circulating half-life to about one week.